Evidence map›Paper›PMID 37492552›Full record

ArticleJournal of public health in Africa2023

Effects of

Fina Luthfiana, Riza Ambar Sari, Irawati Sholikhah, Katsuyoshi Matsunami, Sukardiman, Retno Widyowati

Abstract read
In one paragraph

Article in Journal of public health in Africa, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fina LuthfianaMaster Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Riza Ambar SariMaster Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Irawati SholikhahDepartment of Chemistry, Faculty of Sains and Technology, Universitas Airlangga, Indonesia.
Katsuyoshi MatsunamiDepartment of Pharmacognosy, Graduate School of Biomedical & Health Sciences, Hiroshima University, Japan.
SukardimanDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.
Retno WidyowatiDepartment of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Low bone mass accompanied by microarchitectural alterations in the bone that cause fragility fractures is known as secondary osteoporosis and occurs when there is an underlying condition or medication present. Eleutherine bulbosa bulb extract has been shown to affect bone because of its content, which can help osteoblast differentiation and inhibit osteoclast differentiation. Objective: This study aimed to assess the effects of 70% ethanol extract of Methods: Six groups of 30 female Wistar rats were created. There were no test materials offered to the healthy group; the negative group received 0.5% CMC; the positive group received alendronate 0.9 mg/kg BW; and the dose group received 30, 60, and 120 mg/kg BW. Glucocorticoid (Dexamethasone) 0.1015 mg/kg BW/day induction was given to all groups except the healthy group to create osteoporosis rats for approximately four weeks. Then they were given oral therapy for approximately 28 days. Followed by the determination of blood calcium levels, the number of osteoblast cells, and bone density of the rat femur trabecular. Results: The result showed that Conclusions: The findings indicate that

Indexed as

Bone densityCalciumEleutherine bulbosaOsteoblast cellOsteoporosis

Identifiers

PMID37492552
PMCPMC10365651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.